ArticleCureus2025
Evaluation of Immediate Postpartum Long-Acting Reversible Contraception for Reducing Short-Interval Pregnancies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShort interpregnancy intervals (conception occurring <18 months after delivery or pregnancy loss) are associated with increased risk of adverse outcomes such as preterm delivery, low birth weight, and invasive placental pathologies. To reduce unintended short-interval pregnancy (SIP) among people desiring contraception, our health network in 2019 began offering immediate postpartum long-acting reversible contraception (LARC), using copper and hormonal intrauterine devices (IUDs) and etonogestrel implants. This study evaluated the impact of the initiative on the incidence of SIP at our institution.
methodsWe conducted a retrospective cohort study of patients on government insurance who delivered between July 1, 2019, and March 31, 2020. The exposure of interest was LARC placement in the immediate postpartum period. The outcome of interest was confirmed pregnancy within 18 months of delivery. Exclusion criteria were immediate postpartum sterilization, cesarean or peripartum hysterectomy, or fetal demise. SIP rates were compared between those opting for LARC immediately after delivery (pp LARC group) and those who declined (no pp LARC group). A logistic regression model controlled for potential confounders.
resultsOf the 1,126 patients who met the inclusion criteria, there were 140 in the pp LARC group (68 etonogestrel implant, 54 levonorgestrel IUD, and 18 copper IUD) and 986 in the no pp LARC group. The pp LARC group experienced a lower proportion of SIP (7.9% versus 23.8%, P < 0.001). In adjusted analysis, immediate postpartum LARC reduced the rate of SIP (adjusted risk ratio (ARR): 0.28, 95% confidence interval (CI): 0.14-0.55, P < 0.001).
conclusionProviding LARC shortly after delivery shows promise for patient uptake and prevention of SIP among individuals wishing for contraception. Expanded studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.